Literature DB >> 8149935

Diurnal variations of serum erythropoietin in trained and untrained subjects.

T Klausen1, F Dela, E Hippe, H Galbo.   

Abstract

The diurnal variations of serum-erythropoietin concentration ([s-EPO]) were investigated in six physically trained (T) and eight untrained (UT) men. The T subjects had a higher mean maximal oxygen uptake than UT subjects [75.7 (SEM 1.6) ml.min-1.kg-1 versus 48.3 (SEM 1.4) ml.min-1.kg-1, P < 0.0001] and a lower mean body mass index [BMI, 21.7 (SEM 0.7) kg.m-2 versus 24.4 (SEM 0.6) kg.m-2, P = 0.02]. Each subject was followed individually for 24 h as they performed their normal daily activities. Venous blood samples were collected from awakening (0 min) until the end of the 24-h period (1440 min). Both T and UT had a nadir of [s-EPO] 120 min after awakening [10.0 (SEM 0.3) U.l-1 versus 11.5 (SEM 2.1) U.l-1, P > 0.05]. The UT and T increased their [s-EPO] to peak values at 960 min and 960-1200 min, respectively (ANOVA P = 0.03) after awakening [UT: 18.4 (SEM 2.8) U.l-1; T: 16.2 (SEM 2.5) U.l-1, P > 0.05]. The mean 24-h [s-EPO] were 14.5 (SEM 1.0) U.l-1 and 14.9 (SEM 0.9) U.l-1 in T and UT, respectively (P > 0.05). The individual mean 24-h [s-EPO] were not correlated to body mass, BMI or maximal oxygen uptaken. Significant diurnal variations in [s-EPO] occurred in these healthy subjects irrespective of their levels of physical activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8149935     DOI: 10.1007/bf00241652

Source DB:  PubMed          Journal:  Eur J Appl Physiol Occup Physiol        ISSN: 0301-5548


  13 in total

Review 1.  Erythropoietin: structure, control of production, and function.

Authors:  W Jelkmann
Journal:  Physiol Rev       Date:  1992-04       Impact factor: 37.312

2.  Twenty-four-hour profile of plasma glucose and glucoregulatory hormones during normal living conditions in trained and untrained men.

Authors:  F Dela; K J Mikines; M von Linstow; H Galbo
Journal:  J Clin Endocrinol Metab       Date:  1991-11       Impact factor: 5.958

3.  Serum erythropoietin in cross-country skiers.

Authors:  B Berglund; G Birgegård; P Hemmingsson
Journal:  Med Sci Sports Exerc       Date:  1988-04       Impact factor: 5.411

4.  Urinary uric acid:creatinine ratio, serum erythropoietin, and blood 2,3-diphosphoglycerate in patients with obstructive sleep apnea.

Authors:  J L McKeon; N A Saunders; K Murree-Allen; L G Olson; S Gyulay; J Dickeson; A Houghton; J Wlodarczyk; M J Hensley
Journal:  Am Rev Respir Dis       Date:  1990-07

Review 5.  Renal erythropoietin: properties and production.

Authors:  W Jelkmann
Journal:  Rev Physiol Biochem Pharmacol       Date:  1986       Impact factor: 5.545

6.  Diurnal variation of serum immunomoreactive erythropoietin in a normal subject.

Authors:  P M Cotes; B Brozovic
Journal:  Clin Endocrinol (Oxf)       Date:  1982-10       Impact factor: 3.478

7.  Erythropoietic adaptations to endurance training.

Authors:  L M Weight; D Alexander; T Elliot; P Jacobs
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1992

8.  Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients.

Authors:  C Cahan; M J Decker; J L Arnold; L H Washington; J D Veldhuis; E Goldwasser; K P Strohl
Journal:  J Appl Physiol (1985)       Date:  1992-06

9.  Influence of prolonged physical exercise on the erythropoietin concentration in blood.

Authors:  H J Schwandt; B Heyduck; H C Gunga; L Röcker
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1991

10.  Effects of maximal and submaximal exercise under normoxic and hypoxic conditions on serum erythropoietin level.

Authors:  W Schmidt; K U Eckardt; A Hilgendorf; S Strauch; C Bauer
Journal:  Int J Sports Med       Date:  1991-10       Impact factor: 3.118

View more
  11 in total

Review 1.  Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.

Authors:  Emmanuelle Varlet-Marie; Aurélie Gaudard; Michel Audran; Francoise Bressolle
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

2.  Population pharmacokinetics of darbepoetin alfa in healthy subjects.

Authors:  Balaji Agoram; Liviawati Sutjandra; John T Sullivan
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

3.  Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.

Authors:  Kazuki Kawakami; Hirotaka Takama; Daisuke Nakashima; Hideji Tanaka; Eiji Uchida; Tadao Akizawa
Journal:  Eur J Clin Pharmacol       Date:  2008-09-21       Impact factor: 2.953

4.  Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing.

Authors:  Guohua An; Robin K Ohls; Robert D Christensen; John A Widness; Donald M Mock; Peter Veng-Pedersen
Journal:  J Pharm Sci       Date:  2017-02-09       Impact factor: 3.534

5.  Acute short-term hyperoxia followed by mild hypoxia does not increase EPO production: resolving the "normobaric oxygen paradox".

Authors:  Tadej Debevec; Michail E Keramidas; Barbara Norman; Thomas Gustafsson; Ola Eiken; Igor B Mekjavic
Journal:  Eur J Appl Physiol       Date:  2011-07-07       Impact factor: 3.078

Review 6.  Exercise, training and red blood cell turnover.

Authors:  J A Smith
Journal:  Sports Med       Date:  1995-01       Impact factor: 11.136

Review 7.  Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid.

Authors:  Randall L Wilber
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

8.  Human erythropoietin response to hypocapnic hypoxia, normocapnic hypoxia, and hypocapnic normoxia.

Authors:  T Klausen; H Christensen; J M Hansen; O J Nielsen; N Fogh-Andersen; N V Olsen
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

9.  Diurnal variations of serum erythropoietin at sea level and altitude.

Authors:  T Klausen; T D Poulsen; N Fogh-Andersen; J P Richalet; O J Nielsen; N V Olsen
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

Review 10.  Erythropoietin.

Authors:  W Jelkmann
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.